Research programme: anti-PD1 antibodies - ARMO Biosciences/Ligand Pharmaceuticals

Drug Profile

Research programme: anti-PD1 antibodies - ARMO Biosciences/Ligand Pharmaceuticals

Alternative Names: AM 0001

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Open Monoclonal Technology
  • Developer ARMO Biosciences; Ligand Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD8 positive T lymphocyte stimulants; Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Jun 2018 ARMO Biosciences has been acquired by Eli Lilly
  • 28 Aug 2017 Preclinical trials in Cancer in USA (Parenteral) before August 2017 (ARMO Biosciences pipeline, August 2017)
  • 15 Oct 2015 Early research in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top